A Study of VG712 in Patients With Mycosis Fungoides (NCT07529405)
A Phase II Multi-center Randomized Clinical Trial to Determine the Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (VG712) in Subjects With Mycosis Fungoides (CurbMF Trial)
🩺 Plain-English Summary (8th-Grade Level)
VG712 (A-dmDT390-bisFv(UCHT1) fusion protein) is a recombinant anti-CD3 immunotoxin that selectively depletes CD3-positive T cells through irreversible inhibition of protein synthesis. This Phase II study (CurbMF-001) evaluates the safety and efficacy of VG712 compared with mogamulizumab in subjects with relapsed or refractory mycosis fungoides (MF) who have failed 2 or more prior systemic therapies. The study has two parts: a lead-in dosing part (BOIN design, up to 24 subjects) to determine RP2D, followed by a randomized part (approximately 322 subjects, 1:1 VG712 vs. mogamulizumab). Sponsor: Virogen Biotechnology Inc.
Who can join: Review the eligibility criteria below.
Location: H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
📞 Contact the Study Coordinator
Phone: (925) 699-2195
Email: chensu@virogenbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mycosis Fungoides
- Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome — Basking Ridge, New Jersey
- Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome — St Louis, Missouri
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides — Baltimore, Maryland
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome — Duarte, California
- Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides — Chicago, Illinois
Explore by condition: All Mycosis Fungoides clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.